PhytoNexus

PhytoNexus

Department of Pharmacognosy · Herb-Drug Interaction Intelligence Platform · generated 27 Jul 2026 01:07 IST
Loganiaceae · source entry 53

Strychnos nux-vomica

Nux Vomica

Tier 2 · Verified 3 curated · 6 predicted 4Contraindicated Risk index 92
Interaction profile

01 Identity and provenance

Accepted binomial
Strychnos nux-vomica
Common names
Nux Vomica
Family (APG IV)
Loganiaceae
Part used
Seed
Verification tier
Tier 2 · Verified Clinical columns reviewed and a source is on record.
Reviewer note (2026 audit)
CORRECTED - Active chemical moiety: "Indole nucleus" is a structural feature, not a marker compound. The two principal alkaloids of S. nux-vomica seed are strychnine and brucine. | Chemical composition / class: Class clarified with the pharmacopoeial alkaloid range. | References link: Verified reference added.

02 Constituent chemistry

Chemical classMarker compoundSynthetic analogue in use
Indole alkaloids (2.5-3.5% total) Strychnine, Brucine
Seed
None

The analogue column is what makes the interaction reasoning tractable: where a constituent has a marketed structural counterpart, the counterpart's interaction profile is the starting hypothesis for the plant.

Looking up structures and physicochemical properties from PubChem…

03 Stated application

Reported activity
CNS stimulant ,
Digestive tonic
Marketed in
Homeopathic nux vomics
tablets ordrops,
No allopathic formulation
Reported adverse effects
Muscle twitching,Respiratory failure

04 Interaction matrix

Source column, verbatim: CNS stimulant,Anti epileptic sedative
Normalised onto 3 canonical drug classes below.

Curated from the reviewed source

Drug classSeverityMechanism type ProvenanceExpected effect
Antiepileptics
CNS
3Major PK-CYP induction + PD-antagonistic curated A Breakthrough seizures, status epilepticus, or additive sedation and ataxi… why ▾
CNS stimulants and sympathomimetics
CNS
3Major PD-additive curated A Tachycardia, hypertension, arrhythmia, insomnia, anxiety, stroke and myoc… why ▾
Sedatives, hypnotics and benzodiazepines
CNS
3Major PD-additive curated A Excess sedation, psychomotor and driving impairment, falls, respiratory d… why ▾

Predicted from constituent chemistry

These edges are not clinical findings. Each one is a rule inference: a constituent class in this plant is known to act on a target that the drug class also acts on. They are shown because a blank cell reads as “safe”, and for a Tier 1 entry a blank cell only means “not yet looked at”. Treat them as a literature-search agenda, not as a warning.
Drug classSeverityMechanism type ProvenanceExpected effect
Antidepressants (SSRI, SNRI, TCA)
CNS
4Contraindicated PD-additive serotonergic + PK-CYP2D6 predicted D Serotonin syndrome (agitation, clonus, hyperthermia, autonomic instabilit… why ▾
Antihypertensives
Cardiovascular
4Contraindicated PD-additive predicted D Orthostatic hypotension, dizziness, syncope and falls; or loss of blood-p… why ▾
Cytotoxic and targeted anticancer drugs
Oncology
4Contraindicated PK-CYP3A4/UGT + PD-antagonistic predicted D Neutropenic sepsis and severe diarrhoea from over-exposure, or reduced an… why ▾
Monoamine oxidase inhibitors
CNS
4Contraindicated PD-additive predicted D Hypertensive crisis, hyperpyrexia, serotonin syndrome, intracranial haemo… why ▾
Narrow-therapeutic-index CYP3A4 substrates
Pharmacokinetic
4Contraindicated PK-CYP3A4 predicted D Toxic accumulation or subtherapeutic failure of the co-prescribed drug, s… why ▾
Antacids, PPIs and H2 blockers
Gastrointestinal
2Moderate PK-absorption predicted D Reduced or erratic absorption of alkaloids; heartburn and reflux from pre… why ▾

05 Hazard register

The audit recorded no hazard beyond the interaction profile. The controlled-vocabulary field reads not assessed, which means the assessment has not been done rather than that it came back clear.

06 Confusable material

No same-genus or shared-common-name entry in the corpus.

07 Mechanism map

Chemistry sorts to the left, pharmacology to the right. Dashed edges are predicted. Drag nodes, scroll to zoom, export at 3× for a figure.

species
chemical class
marker compound
drug class
expected effect
hazard

08 Open literature

Abstract-scoped query built from this binomial, its common names and its marker compounds, run live against Europe PMC, PubMed and OpenAlex, then ranked locally against an evidence hierarchy.

Checking openFDA spontaneous reports…

09 Isomechanistic neighbours

Species whose interaction profile overlaps this one, ranked by shared severity weight rather than by count — a shared contraindication counts for more than a shared minor signal. Practical use: these are the plants you should not stack with this one, because the mechanisms summate.

SpeciesFamilyShared classes WeightJaccard
Peganum harmala
Syrian Rue
Nitrariaceae 7 0.70
Mitragyna speciosa
Kratom
Rubiaceae 7 0.64
Rauvolfia serpentina
Sarpagandha
Apocynaceae 6 0.67
Catharanthus roseus
Periwinkle
Apocynaceae 6 0.67
Alstonia scholaris
Saptaparna
Apocynaceae 6 0.67
Physostigma venenosum
Calabar Bean
Fabaceae 6 0.55

10 References and notes

Source column: https://www.jbclinpharm.org/articles/strychnos-nuxvomica-a-poisonous-plant-with-various-aspects-of-therapeutic-significance.pdf

BibTeX for all 1 records
@article{anon,
  url = {https://www.jbclinpharm.org/articles/strychnos-nuxvomica-a-poisonous-plant-with-various-aspects-of-therapeutic-significance.pdf},
}

Curator notes

No notes yet.

Sign in to add notes and save monographs.